Reid Hoffman leaves Microsoft board to focus on AI drug startup Manus
Reid Hoffman is stepping down from Microsoft’s board after nearly a decade, with the departure disclosed in a regulatory filing. He joined in 2016 following Microsoft’s $26.2 billion acquisition of…
Read the full articleYou might also wanna read
Reid Hoffman sharply criticizes Elon Musk's AI ventures, calls xAI a 'complete train wreck'
The LinkedIn co-founder and investor in both Anthropic and OpenAI offers his most pointed public assessment yet of Elon Musk's AI ambitions.
fortune.com·22d agoReid Hoffman sharply criticizes Elon Musk's AI ventures, calls xAI a 'complete train wreck'
The LinkedIn co-founder and investor in both Anthropic and OpenAI offers his most pointed public assessment yet of Elon Musk's AI ambitions.
fortune.com·22d agoOpenAI Researcher in Talks to Launch AI Drug Discovery Startup at $2B Valuation
Miles Wang, a researcher at OpenAI, is reportedly in discussions to launch a new startup focused on AI-driven drug discovery. The venture is
OpenAI Faces Another Blow On Road To IPO: Ailment Forces AGI Chief Fidji Simo To Leave After Less Than A Year
OpenAI has seen a string of high-profile departures in recent months, including Chief Product Officer Kevin Weil and Vice President of Engin
Ex-OpenAI Researcher Miles Wang Plans $2B AI Drug Discovery Startup
OpenAI researcher Miles Wang is leaving to start an AI drug discovery company, reportedly in talks to raise $200M at a $2B valuation led by
OpenAI researcher leaves to launch AI drug start-up
Miles Wang, a prominent researcher at OpenAI, is leaving the company to start his own venture. His new start-up will focus on using artifici
OpenAI Researcher Miles Wang Is in Talks to Launch a $2 Billion AI Drug Discovery Startup
OpenAI researcher Miles Wang is reportedly launching an AI drug discovery startup, signaling soaring investor interest in biotech AI. The po
Comments
Sign in to join the conversation.
No comments yet. Be the first.